JPY5,135.00
0.86%
Tokyo, Sep 13, 08:15 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY5,135.00
-623.00 10.82% 1M
+501.00 10.81% 6M
+1,263.00 32.62% YTD
+1,028.00 25.03% 1Y
+2,333.00 83.26% 3Y
+2,822.00 122.01% 5Y
+4,518.33 732.70% 10Y
Tokyo, Closing price Fri, Sep 13 2024
+44.00 0.86%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY9.80t
Enterprise Value JPY9.10t
P/E (TTM) P/E ratio 42.95
EV/FCF (TTM) EV/FCF 20.20
EV/Sales (TTM) EV/Sales 5.39
P/S ratio (TTM) P/S ratio 5.81
P/B ratio (TTM) P/B ratio 5.70
Dividend yield 1.17%
Last dividend (FY25) JPY60.00
Revenue growth (TTM) Revenue growth 25.06%
Revenue (TTM) Revenue JPY1.69t
EBIT (operating result TTM) EBIT JPY206.07b
Free Cash Flow (TTM) Free Cash Flow JPY450.50b
Cash position JPY805.26b
EPS (TTM) EPS JPY119.55
P/E forward 46.67
P/S forward 5.41
EV/Sales forward 5.02
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a DAIICHI SANKYO forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a DAIICHI SANKYO forecast:

Buy
87%
Hold
13%

Financial data from DAIICHI SANKYO

Jun '24
+/-
%
Net Profit 229,101 229,101
55% 55%
14%
Depreciation and Amortization 62,092 62,092
7% 7%
4%
Stock Compensation - -
-
-
Operating Cash Flow 535,454 535,454
501% 501%
32%
Investments 128,296 128,296
74% 74%
8%
Dividend Paid 95,855 95,855
67% 67%
6%
Free Cash Flow 450,496 450,496
2,305% 2,305%
27%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Sunao Manabe
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today